Clarity's Cu-64 SAR-bisPSMA lands first PSMA-PET breakthrough designation

Clarity Pharmaceuticals said on 12 November 2026 that the FDA granted Breakthrough Therapy designation to Cu-64 SAR-bisPSMA, its copper-64 PSMA PET imaging agent, for detecting biochemical recurrence of prostate cancer. The company characterizes it as the first Breakthrough Therapy designation in PSMA PET imaging ^[1]. Prognyx read the designation in Clarity's own release; no FDA database entry was available to confirm it independently as of this briefing.

Biochemical recurrence, a rising PSA after primary treatment with no visible disease, is the exact setting where the installed base of PSMA tracers already competes. At least seven PSMA PET products carry an FDA label for imaging suspected recurrence on elevated PSA: gallium-68 PSMA-11 (gozetotide), PYLARIFY and PYLARIFY TRUVU (piflufolastat F-18), POSLUMA (flotufolastat F-18), ILLUCCIX, LOCAMETZ and Gozellix ^{[2][3][4][5][6][7][8]}. The therapeutic side of the ecosystem is anchored by PLUVICTO, the approved PSMA radioligand therapy ^[9]. A breakthrough tag does not clear a path through that field; it signals the FDA sees a plausible case for a meaningful improvement over what exists.

The case rests on detection. Two secondary trade-press pickups, OncLive and Urology Times, reported in October 2025 that the head-to-head Co-PSMA study found Cu-64 SAR-bisPSMA more than doubled prostate-cancer lesion and patient detection versus standard-of-care gallium-68 PSMA-11 ^[10][11]. Prognyx could not read the primary Co-PSMA trial record or a peer-reviewed dataset behind that figure, so treat the "more than doubled" number as trade-press reporting rather than a verified endpoint.

Who is exposed. The agents approved for the same rising-PSA setting, gallium-68 PSMA-11, PYLARIFY, POSLUMA, ILLUCCIX and Gozellix, are the direct competitive surface if Cu-64 SAR-bisPSMA converts a detection edge into a label ^{[2][3][5][6][8]}. Telix Pharmaceuticals sits on both sides of the trade, with ILLUCCIX and Gozellix in this imaging setting ^[6][8]. A tracer that detects disease in more patients reshapes referral patterns in recurrence workups and feeds the downstream radioligand-therapy decision; that is the strategic reason incumbents should care, beyond the single designation.

What breakthrough status does and does not buy. The designation gives Clarity more intensive FDA guidance and eligibility for rolling and priority review. It is not an approval, and it carries no decision date. The dossier contains no NDA filing, no acceptance date and no target action date, and Breakthrough Therapy designation itself starts no review clock, so no US decision window can be placed on a calendar from what is public here. Anyone modelling a timeline is modelling an unannounced filing.

What to watch. The near-term catalysts are a Clarity NDA submission for the biochemical-recurrence indication and release of the Co-PSMA data in a primary venue; neither carries a date in the public record Prognyx reviewed. An ASX disclosure or an FDA database entry would upgrade the designation from a company claim to an independently confirmable fact.

The now-what. For an incumbent in PSMA imaging: pull the Co-PSMA readout the moment it reaches a primary venue and benchmark your tracer's per-patient detection against the "more than doubled" claim before it hardens into a selling point. For a BD team: the window to engage Clarity is now, while the asset is pre-filing and the designation is fresh, rather than after an accepted NDA resets the price. For a radioligand-therapy franchise: a better recurrence-stage imaging agent widens the funnel you depend on, which argues for partnership over defense.

What Prognyx could not verify. The designation rests on Clarity's release, with no FDA.gov or Breakthrough Therapy database confirmation in hand. No ClinicalTrials.gov identifier for the biochemical-recurrence registrational trial was in the record. The Co-PSMA detection figures come from trade-press pickups, not a primary dataset. No pricing, NDA filing date or regulatory timeline is public.

Verdict: the designation is a credible early signal with limited immediate market impact. Threat to incumbents is low today and rises only on an accepted NDA; the window to act, whether to benchmark or to partner, is the pre-filing months that start now.